Bladder Cancer References

Last updated: 11 November 2024
  1. Babjuk M, Bohle A, Burger M, et al. Guidelines on non-muscle-invasive bladder cancer (Ta, T1 and CIS). European Association of Urology. http://www.uroweb.org/guidelines/. Mar 2015. Accessed 28 Jan 2016.
  2. Committee for Establishment of the Clinical Practice Guidelines for the Management of Bladder Cancer, Japanese Urological Association. Evidence-based clinical practice guidelines for bladder cancer (summary-JUA 2009 edition). Int J Urol. 2010 Feb;17(2):102-124. doi: 10.1111/j.1442-2042.2010.02486.x. Accessed 17 Dec 2015. PMID: 20377834
  3. Graham D, Raghavan D, Haggstrom DE, et al. Overview of the management of bladder cancer in older adults. UptoDate. https://www.uptodate.com. Nov 2015. Accessed 17 Dec 2015.
  4. Jimenez JA, Campbell SC, Jones JS. Screening for bladder cancer. UptoDate. https://www.uptodate.com. Nov 2015. Accessed 17 Dec 2015.
  5. Lotan Y, Choueiri TK. Clinical presentation, diagnosis and staging of bladder cancer. UptoDate. https://www.uptodate.com. 13 Feb 2020. Accessed 17 Dec 2015.
  6. National Cancer Center Singapore. Bladder cancer. NCCS. http://www.nccs.com.sg/. 2015. Accessed 28 Jan 2016.
  7. National Collaborating Center for Cancer. Bladder cancer: diagnosis and management NICE guideline 2. National Institute for Health and Care Excellence. http://www.nice.org.uk. Feb 2015. Accessed 7 Jan 2016.
  8. National Comprehensive Cancer Network. NCCN clinical practice guidelines on bladder cancer version 2.2015. NCCN. https://www.nccn.org. 2015. Accessed 17 Dec 2015.
  9. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines) - Asia consensus statements: bladder cancer. NCCN. http://www.nccn.org. 2016. Accessed 25 Jan 2016.
  10. Umbas R, Safriadi F, Mochtar CA, et al. Urologic cancer in Indonesia. Jpn J Clin Oncol. 2015 Aug;45(8):708-712. doi: 10.1093/jjco/hyv06. Accessed 28 Jan 2016. PMID: 26085688
  11. Witjes JA, Comperat E, Cowan NC, et al. Guidelines on muscle-invasive and metastatic bladder cancer. European Association of Urology. http://www.uroweb.org.guidelines/. Mar 2015. Accessed 28 Jan 2016.
  12. Witjes JA, Comperat E, Cowan NC, et al. Guidelines on muscle-invasive and metastatic bladder cancer. European Association of Urology. http://www.uroweb.org/guidelines/. 2016. Accessed 27 Jun 2016.
  13. National Comprehensive Cancer Network. NCCN clinical practice guidelines on bladder cancer. version 2.2016. NCCN. http://www.nccn.org. 2016. Accessed 8 Sep 2016.
  14. Babjuk M, Bohle A, Burger M, et al. Guidelines on non-muscle-invasive bladder cancer. European Association of Urology. http://www.uroweb.org/guidelines/. 2016. Accessed 27 Jun 2016.
  15. Babjuk M, Boehle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. PMID: 27324428
  16. Babjuk M, Burger M, Comperat E, et al. EAU Guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). European Association of Urology. https://www.uroweb.org/. Mar 2021. Accessed 02 Jul 2018.
  17. National Comprehensive Cancer Network. NCCN clinical practice guidelines on bladder cancer. version 4.2018. NCCN. https://www.nccn.org. 22 May 2018. Accessed 02 Jul 2018.
  18. Nishiyama H. Asia consensus statement on NCCN clinical practice guideline for bladder cancer. Jpn J Clin Oncol. 2018 Jan;48(1):3-6. doi: 10.1093/jjco/hyx130. PMID: 29145591
  19. Roupret M, Babjuk M, Comperat E, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol. 2018 Jan;73(1):111-122. doi: 10.1016/j.eururo.2017.07.036. PMID: 28867446
  20. Witjes JA, Bruins M, Comperat E, et al. EAU 2018 updated guidelines on muscle-invasive and metastatic bladder cancer. European Association of Urology. http://uroweb.org/. 2018.
  21. Witjes JA, Lebret T, Comperat EM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017 Mar;71(3):462-475. doi: 10.1016/j.eururo.2016.06.020. PMID: 27375033
  22. American Cancer Society. Bladder cancer surgery. ACS. https://www.cancer.org/. Jan 2019.
  23. American Cancer Society. Key statistics for bladder cancer. ACS. https://www.cancer.org/. Jan 2020.
  24. Babjuk M, Burger M, Comperat E, et al for the European Association of Urology. Non-muscle-invasive bladder cancer. EAU. https://uroweb.org/. 2020.
  25. Cancer Research UK. Bladder cancer statistics. Cancer Research UK. https://www.cancerresearchuk.org/. Mar 2020.
  26. ESMO Guidelines Committee. eUpdate – Bladder Cancer Treatment Recommendations. ESMO. http://www.esmo.org/. 16 Dec 2019.
  27. National Cancer Institute - Surveillance, Epidemiology, and End Results Program. Cancer stat facts: bladder cancer. NCI SEER. https://seer.cancer.gov/. 2020.
  28. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): Bladder cancer. Version 3.2020. NCCN. https://www.nccn.org/. 17 Jan 2020.
  29. Witjes JA, Bruins HM, Cathomas R, et al for the European Association of Urology. Muscle-invasive and metastatic bladder cancer. EAU. https://uroweb.org/. 2020.
  30. World Cancer Research Fund. Bladder cancer statistics. WCRF. https://www.wcrf.org/. 2020.
  31. Bellmunt J. Treatment of metastatic urothelial cancer of the bladder and urinary tract. UpToDate. https://www.uptodate.com. 21 Jun 2021.
  32. Bhindi B, Kool R, Kulkarni GS, et al. Canadian Urological Association guideline on the management of non-muscle invasive bladder cancer. Can Urol Assoc J. 26 Apr 2021. doi: 10.5489/cuaj.7367. PMID: 33938798
  33. ClinicalKey. Bladder cancer. ClinicalKey. https://www.clinicalkey.com. 20 May 2021.
  34. Witjes JA, Bruins HM, Cathomas R, et al. EAU Guidelines on muscle-invasive and metastatic bladder cancer. European Association of Urology. https://www.uroweb.org/. Mar 2021. Accessed 16 Jul 2021.
  35. Kulkarni GS, Black PC, Sridhar SS, et al. Canadian Urological Association guideline: Muscle-invasive bladder cancer. Can Urol Assoc J. 2019 Jan;13(8):230-238. doi: 10.5489/cuaj.5902. PMID: 30763236
  36. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: bladder cancer, version 3.2021. NCCN. https://www.nccn.org/. 22 Mar 2021.
  37. U.S. Food and Drug Administration. Trodelvy prescribing information. US FDA. http://www.fda.gov. 2020.
  38. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: bladder cancer. Version 4.2021. NCCN. https://www.nccn.org/. 27 Jul 2021.
  39. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: bladder cancer. Version 3.2023. NCCN. https://www.nccn.org/. 25 May 2023.